BridgeMD
(PLASTIC-3) [18F]FAPI-PET/CT and Laparoscopy in STagIng advanced gastric Cancer – a multicenter prospective study
EU CTIS ID: 2024-513255-32-00
What this study is testing
To assess the applicability and impact of [18F]AlF-FAPI-74 PET/CT as a non-invasive imaging biomarker to optimize whole body staging of locally advanced gastric cancer, limiting the need for staging laparoscopy
- Phase II and Phase III (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Histologically proven adenocarcinoma of the stomach or the esophagogastric junction (Siewert type III), by gastroscopy
- Age greater than or equal to 18 years
- Surgically resectable, advanced tumor (cT3-4b, N0-3, M0), as determined on gastroscopy and a contrast-enhanced CT of thorax and abdomen. Intention to perform a gastrectomy, based on a multidisciplinary team meeting and shared decision making
- Patients must have given written informed consent
- Patients who have recently participated in an interventional study with an investigational medicinal product (IMP) may only participate if an interaction with study procedures is deemed unlikely by the study team (e.g. based on mechanism or washout period)
You likely can't join if
- Siewert type I-II esophagogastric junction tumor
- Unfit or unwilling to undergo study procedures
- Unfit or unwilling to undergo surgery
- Pregnancy at time of the [18F]AlF-FAPI-74 PET/CT scan, due to the investigational PET radiation burden
- Incapacitated subjects without decision-making capacity
- Medical or psychiatric conditions that compromise the patient’s ability to give informed consent
See the full eligibility criteria
- Histologically proven adenocarcinoma of the stomach or the esophagogastric junction (Siewert type III), by gastroscopy
- Age greater than or equal to 18 years
- Surgically resectable, advanced tumor (cT3-4b, N0-3, M0), as determined on gastroscopy and a contrast-enhanced CT of thorax and abdomen. Intention to perform a gastrectomy, based on a multidisciplinary team meeting and shared decision making
- Patients must have given written informed consent
- Patients who have recently participated in an interventional study with an investigational medicinal product (IMP) may only participate if an interaction with study procedures is deemed unlikely by the study team (e.g. based on mechanism or washout period)
- Siewert type I-II esophagogastric junction tumor
- Unfit or unwilling to undergo study procedures
- Unfit or unwilling to undergo surgery
- Pregnancy at time of the [18F]AlF-FAPI-74 PET/CT scan, due to the investigational PET radiation burden
- Incapacitated subjects without decision-making capacity
- Medical or psychiatric conditions that compromise the patient’s ability to give informed consent
- Illiterate patients unable to complete the resource use and quality of life questionnaires
- Inability to undergo PET/CT scans due to factors such as claustrophobia, weight limits, or the inability to lie flat for the duration of the scan (approximately 30 minutes)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.